Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Many patients with obsessive-compulsive disorder do not respond adequately to serotonin reuptake inhibitors. Augmentation with antipsychotic drugs can be beneficial in this regard. However, since new relevant randomized controlled trials evaluating new antipsychotics were conducted, a recalculation of the effect sizes appears necessary. We meta-analyzed all double-blind, randomized, placebo-controlled trials comparing augmentation of serotonin reuptake inhibitors with antipsychotics to placebo supplementation in treatment-resistant obsessive-compulsive disorder. The primary outcome was mean change in the Yale-Brown Obsessive–Compulsive Scale total score. Secondary outcomes were obsessions, compulsions, response rates, and attrition rates. The data collection process was conducted independently by 2 authors. Hedges’s g and risks ratios were calculated as effect sizes. In preplanned meta-regressions, subgroup analyses, and sensitivity analyses, we examined the robustness of the results and explored reasons for potential heterogeneity. Altogether, 14 double-blind, randomized, placebo-controlled trials (n=491) investigating quetiapine (N=4, n=142), risperidone (N=4, n=132), aripiprazole (N=2, n=79), olanzapine (N=2, n=70), paliperidone (N=1, n=34), and haloperidol (N=1, n=34) were incorporated. Augmentation with antipsychotics was significantly more efficacious than placebo in Yale-Brown Obsessive–Compulsive Scale total reduction (N=14, n=478; Hedges’s g=-0.64, 95% CI: -0.87 to -0.41; P=<.01). Aripiprazole (Hedges’s g=-1.35), haloperidol (Hedges’s g=-0.82), and risperidone (Hedges’s g=-0.59) significantly outperformed placebo. Antipsychotics were superior to placebo in treating obsessions, compulsions, and achieving response. There was no between-group difference concerning all-cause discontinuation. The nonsignificant meta-regressions suggest no influence of the antipsychotic dose or baseline symptom severity on the meta-analytic results. According to our findings, antipsychotic augmentation of serotonin reuptake inhibitors can be regarded as an evidence-based measure in treatment-resistant obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.](https://figures.cochat.ai/paper-figures/557e47f3e0974917a52a232803937ae6/antipsychotic-augmentation-of-serotonin-reuptake-inhibitors-in-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst dopaminergic medications are not first-line treatments for OCD, dopamine receptor antagonists are often used to augment first-line treatment in refractory cases (Hirschtritt et al. 2017) and the efficacy of this strategy is confirmed by meta-analyses (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
In the citing paper
“meta-analysis confirms that dopamine receptor antagonists reduce obsessive-compulsive symptoms in SSRI-refractory OCD (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“A potential publication bias was examined by funnel-plot visualization and accomplishment of Egger`s regression intercept test (2-tailed) (Egger et al., 1997).”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Haenszel random-effects model of Der-Simonian and Laired (Der-Simonian and Laird, 1986)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“…tic disorder (McDougle et al., 1994, 2000; Shapira et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Fineberg et al., 2005; Kordon et al., 2008; Simpson et al., 2013) did not alter the combined overall effect sizes in terms of statistical significance (N = 6, n = 195; Hedges’s g =…”
BackgroundA Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 1×
“Moreover, we estimated the number of negative unpublished trials (fail-safe N value) that would be necessary to dissolve statistically significant differences (Orwin, 1983).”
BackgroundInternational Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 3×
“In unrestricted maximum-likelihood meta-regression analyses, we investigated the impact of the continuous moderators: (1) mean administered antipsychotic dose (calculated as olanzapine equivalents according to the International Consensus Study of Antipsychotic Dosing [Gardner et al., 2010]); and (2) baseline symptom s…”
MethodInfluentialKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Research works printed but not linked: 2
- Borenstein, 2006, Comprehensive meta-analysis, version 2
- The Cochrane Collaboration, 2014, Review Manager (RevMan) [Computer program]. Version 5.3
Cited by
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
“0b013e318185e735] [PMID: 18794652] [148] Dold, M.”
BackgroundInfluentialFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“…there is randomized controlled trial (RCT) and meta-analytic evidence to support augmentation with an second-generation antipsychotic (Brakoulias and Stockings, 2019; Dold et al., 2015; Stein et al., 2012; Zhou et al., 2019); however, the use of these agents would be considered off-label.”
BackgroundClinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
Kim, S. J., Roh, D., Jung, H. H., Chang, W. S., Kim, C.-H., & Chang, J. W. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170188 · Cited by 121
Metadata
- Authors
- Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S.
- Affiliations
- Universitätsklinikum Tulln (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-04
- Volume
- 18
- Issue
- 9
- Pages
- pyv047
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4576518
- OpenAlex
- W4244844159
- Cited by
- 134
- References
- 49
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 16 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 7 · 2015: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- H. Lundbeck A/S
- Cilag
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- treatment-resistant OCD, antipsychotic augmentation, serotonin reuptake inhibitors, quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol, Yale-Brown Obsessive Compulsive Scale, obsessions and compulsions, treatment response, attrition, antipsychotic dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. https://app.cochat.ai/papers/10.1093/ijnp/pyv047
- The paper
- Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyv047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.